• PODCASTS FROM ICAAC 2007
Interviews With HIV Experts on the Latest Research
Important new HIV research was presented at ICAAC 2007 last week in Chicago, Ill., and TheBody.com was there to cover it! We interviewed researchers regarding their own studies, and spoke to
clinicians and researchers about what they thought were the key presentations. Check back to make sure you don't miss a thing! Additional transcripts and MP3 podcasts will be added regularly.
Click here for a full list of ICAAC interviews.
- Trevor Hawkins, M.D., offers his perspective on the most critical news from ICAAC, including research on the new CCR5 inhibitors, and a study showing that Prezista (darunavir, TMC114) + Norvir (ritonavir) matched -- and in certain people outperformed -- Kaletra (lopinavir/ritonavir).
- Joseph J. Eron, M.D., discusses the 48-week results of a study examining the new integrase inhibitor raltegravir (MK-0518) in highly treatment-experienced patients.
- Roy Gulick, M.D., M.P.H., discusses the results of a two-year study on treatment-experienced people taking vicriviroc, a CCR5 inhibitor in development.
• HIV TREATMENT & COMPLICATIONS
A Roadmap to Today's HIV Complications
Improvements in HIV treatment have dramatically changed life with HIV over the last 10 years. HIVers with access to treatment can
now hope to live long, healthy lives, largely free of the opportunistic infections that are traditionally associated with untreated HIV. However, there's a new generation of HIV-related health complications
to stay on top of. Check out this article from Positively
a list of things to watch out for, and what you can do to protect yourself.
• HIV ACTIVISM
Planning a World AIDS Day Event?
World AIDS Day is just two months away, so if you're thinking of organizing an event for Dec. 1, there's no time like the present to start getting ready! Check out our collection of handy tips on how
to put together a memorable World AIDS Day event.
• LIVING WITH HIV
Rejected Because of Your HIV Status? It's Their Loss!
When his partner of four years left him, saying that he couldn't feel comfortable with an HIV-positive man, Jack Degnan searched for an explanation. Now an HIV health worker, Degnan helps other people explore how an irrational fear of being infected and the desire for unprotected sex sometimes make HIV-negative people reject HIV-positive partners. He's come to see this rejection as a gift, however: "I like to think of having HIV as a screening tool," Degnan says. "Anyone who is unable to look beyond my virus is not the kind of person I want to spend time with anyway."
• HIV RESEARCH
Herpes Treatment to Prevent HIV? A Review of This Summer's Research
Could treating genital herpes help prevent HIV? Recent studies have shown that people with genital herpes and HIV might be more likely to transmit HIV, and HIV-negative folks experiencing
herpes outbreaks might be especially vulnerable to HIV. This suggests that herpes treatment may help reduce a person's risk of both getting and transmitting HIV. This research recap from the Community
HIV/AIDS Mobilization Project discusses the latest study results on genital herpes medication for HIV prevention.
Another HIV Vaccine Bites the Dust
The clinical trial of an HIV vaccine that experts considered one of the most promising vaccines in development was stopped last week after researchers found that it failed to prevent HIV infections or
reduce the amount of virus in study participants who became HIV positive. The vaccine was supposed to stimulate an increased CD4 cell response that researchers hoped would fight off HIV infection or progression.
The executive director of the AIDS Vaccine Advocacy Coalition tried to put a positive spin on the findings: "It isn't the end of the line," he said. "[The data] aren't the answers we wanted, but they will
help improve our other vaccine candidates."
Click here to read the announcement from the vaccine maker about the trial's discontinuation.
• HIV IN THE U.S. NEWS
Black Leaders Come Together for Historic Meeting to End HIV
The National Black Leadership Commission on AIDS (NBLCA) is hosting what it says is the first-ever conference dedicated to developing a five-year plan to significantly reduce HIV cases among African Americans.
The meeting will be held in New York City in early October. African Americans account for about 13 percent of the U.S. population, but made up about half of new AIDS diagnoses in the United States in 2005,
according to the U.S. Centers for Disease Control and Prevention. "It's a crisis," said Rev. Dr. Calvin O. Butts, III, the chairman of the board for the NBLCA. "Once you hear the numbers, you realize the
impact, the unthinkable loss of lives that we as a community are facing. You absolutely know that a lot of this could be prevented." (Web highlight from EURweb.com)
U.S. Presidential Candidate Edwards Details His Plan to Fight HIV
Former Senator and 2008 U.S. presidential hopeful John Edwards has publicly detailed how he would fight HIV if elected president. At a health care forum in Washington, D.C., the Democratic candidate called
for spending $50 billion over five years to provide worldwide, universal access to HIV prevention and treatment. On the home front, Edwards says he would expand Medicaid coverage to include HIVers before they
progress to AIDS, increase HIV prevention resources in black and Hispanic communities, ensure comprehensive sex education, and lift the ban on federal funding for needle-exchange programs.
To stay on top of the latest news involving HIV and the 2008 U.S. presidential election, keep an eye on our election 2008 page.
Click here for John Edwards' complete HIV platform.
• HIV OUTSIDE THE UNITED STATES
UNAIDS to Wealthy Nations: To Stop HIV, We Must Have More Money
A massive inflow of cash is the only way that UNAIDS can meet its commitment to provide the entire developing world with access to HIV prevention, treatment and care by 2010, the group reported this week.
The price tag for universal access? About US$42 billion, UNAIDS says -- dramatically more money than it currently gets from wealthy donor countries. UNAIDS also warns that the funding
situation is actually getting worse, not better: "If current trends continue, the gap between resources available and resources needed to achieve global objectives will widen each year through
organization reports. (Web highlight from aidsmap.com)
Click here to download a brief summary of the UNAIDS report, or click here to
download the report in its entirety.
Using HIV Drugs for Prevention Could Avoid Three Million Infections in Africa
As many as three million new HIV infections could be prevented in sub-Saharan Africa over the next 10 years if Viread (tenofovir) is used before a potential exposure, according to U.S. and United
Kingdom researchers. The researchers calculated that widespread, daily use of Viread by sexually active adults in sub-Saharan Africa could reduce new HIV cases by as much as 74 percent. The estimated cost:
US$2 billion over 10 years -- that's $1.2 billion less than what was spent on HIV prevention worldwide by UNAIDS in 2005 alone.
Click here to read the study abstract in the Sept. 19 edition of the online journal PLoS One.
Rwanda: Calling All Uncircumcised Males!
By now we've all heard that male circumcision can reduce a man's risk of HIV infection through heterosexual sex by more than half. Because of this, the Rwandan government has announced plans for a massive
male circumcision program, which will begin by targeting the army, police and students in higher education. Funding for the campaign may come at least partially from the U.S. President's Emergency Plan
for AIDS Relief.
AIDS Crisis Politicized in South Africa as Death Toll Mounts
Nearly 1,000 South Africans die from AIDS-related illnesses every day, health advocates say, but the response of South Africa's president, Thabo Mbeki, has been sluggish and inconsistent. In a meeting
this December, South Africa's ruling party -- the African National Congress (ANC) -- is expected to consider its next leader. Activists will urge the ANC to make HIV treatment a national priority and denounce
President Mbeki. (Web highlight from National Public Radio)